Panobinostat (LBH589)

For research use only. Not for use in humans.

目录号:S1030 别名: NVP-LBH589 中文名称:帕比司他

Panobinostat (LBH589) Chemical Structure

CAS No. 404950-80-7

Panobinostat (LBH589, NVP-LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Panobinostat (LBH589) 可诱导自噬和凋亡。Panobinostat 可以有效地破坏体内 HIV 的潜伏期。Phase 3。

规格 价格 库存 购买数量  
RMB 731.86 现货
RMB 2189.52 现货
RMB 5485.18 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Panobinostat (LBH589)发表文献269篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Panobinostat (LBH589, NVP-LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Panobinostat (LBH589) 可诱导自噬和凋亡。Panobinostat 可以有效地破坏体内 HIV 的潜伏期。Phase 3。
靶点
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
体外研究

LBH589诱导MOLT-4和Reh细胞凋亡,这种作用具有时间和剂量依赖性。而且,LBH589作用于MOLT-4细胞比作用于Reh细胞更有效。LBH589明显阻止MOLT-4 和Reh细胞的生长,处理48小时,具有剂量依赖性。与对照组细胞相比,用LBH589处理的细胞,在细胞周期的G2/M期的细胞数量增多2到3倍。LBH589与组蛋白H3K9和H4K8的乙酰化作用相关,LBH589也降低c-Myc的表达水平,具有剂量依赖性。LBH589也增强p21的表达水平。最低剂量的LBH589(10 nM)处理Reh细胞,最初增强c-Myc的表达水平,之后一直降低c-Myc的表达水平。此外,LBH589促进mRNA水平的促凋亡和DNA修复基因的大量增多。在GADD45G启动子作用下,LBH589诱导乙酰化的组蛋白H3 和H4水平的增多。[1]此外, LBH589抑制非小细胞肺癌细胞系生长,如人类H1299,L55和A549,IC50分别为5,11和30 nM;间皮瘤细胞生长,如人类OK-6和 Ok-5,IC50分别为5和7 nM;及小细胞肺癌细胞系生长,如人类RG-1和LD-T,IC50分别为4和5 nM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NGnTNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jSO|AuOTBizszN NXe4dZd4OC12IHS= MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1\aUVI3PzB{N{i0
HepG2 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYriXmNEOC1zMDFOwG0> NH\yPGQxNTRiZB?= NHn0dJdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWeyOlcxOjd6NB?=
HT29 M{PnNmZ2dmO2aX;uJGF{e2G7 NVTqZWFRPTEEoH7N NHzoVJIzPC15MjDo MonXbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkA1QMLiaNMg MU[yOlcxOjd6NB?=
HepG2 NXrPZnJsTnWwY4Tpc44hSXO|YYm= MYK1NOKhdk1? NUS5XJpROjRvN{KgbC=> NFr3WFBqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDJ2wrDoxsA> NXLSPXRVOjZ5MEK3PFQ>
HCC827 M2LXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXG1M|cvPS9zMDDuUS=> MV23NuKhcA>? MmW3SG1UVw>? M2G1foVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk NHvHS2YzPjZ5NUS4OC=>
A549  MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfQXooyOTBxMUWvNlAhdk1? M4LMSlczyqCq NIKy[HJFVVOR NVjDbXR2\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= MnqxNlY3PzV2OES=
NCI-H460  M{i0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M372e|ExNzJyL{OwJI5O M2XrflczyqCq Mm\jSG1UVw>? NX3UZ2tQ\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= NFvCb5UzPjZ5NUS4OC=>
J89GFP M{jWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnEUXNQyqB? MnHFSWM2OD12OT64OUDDuSBzMj62OUBvVQ>? NHLXe2UzPjV4M{W2PC=>
THP89GFP NInN[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\EUXNQyqB? NXW4UXBLTUN3ME2xPU4{PCEEsTC2MlQ{KG6P MkLxNlY2PjN3Nki=
SK-NEP-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;rWWp{OC5yMfMAl|ExNjBizszN NHXYZZkzPCCq M1LI[2ROW00EoB?= NFT5dWhKSzVyPUe2MlM1KG6P NYTYOXZXOjZzN{[yNVk>
G401 MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfv[HFlOC5yMfMAl|ExNjBizszN NYW4dnZIOjRiaB?= MXTEUXNQyqB? MUfJR|UxRTF2Mz6wNkBvVQ>? MXyyOlE4PjJzOR?=
SK-NEP-1 MWLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWrBV3FJPTBibl2= NEm5OnYy6oDVNDDk M3PrVmROW00EoB?= MYTy[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> Mnz4NlYyPzZ{MUm=
G401 MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mm\lOVAhdk1? M1zLblHjiJN2IHS= Mm\nSG1UV8Li NEHrb5lz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? Ml;sNlYyPzZ{MUm=
SK-NEP-1 NWfBPJJESXCxcITvd4l{KEG|c3H5 Mn\ZOVAwOTByIH7N NXT4e2hXOjRiaB?= M3vwe2ROW00EoB?= NETNcVdqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NITHO3kzPjF5NkKxPS=>
G401 NHiyV|NCeG:ydH;zbZMhSXO|YYm= MYC1NE8yODBibl2= M4nqNlI1KGh? M3OzWmROW00EoB?= MlrBbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M1XiZVI3OTd4MkG5
SK-NEP-1 MXTGeY5kfGmxbjDBd5NigQ>? M{DHRVUxNzFyMDDuUS=> M{XMWlI1KGh? MUfEUXNQyqB? MmDMd4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? M3\TXFI3OTd4MkG5
G401 Mk\MSpVv[3Srb36gRZN{[Xl? MYq1NE8yODBibl2= MUmyOEBp NVLvW3JUTE2VT9Mg M2\M[pNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? MnvONlYyPzZ{MUm=
SK-NEP-1 M1TIU2Z2dmO2aX;uJGF{e2G7 MnS3OVAwOTByIH7N NXvIPIJ3OjRiaB?= MnXUSG1UV8Li NXvtTXJkcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? M1;pZ|I3OTd4MkG5
G401 Mn;jSpVv[3Srb36gRZN{[Xl? NGrtXFI2OC9zMECgcm0> Mnu0NlQhcA>? MlrHSG1UV8Li NY\5PFZ6cW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? M2XTdFI3OTd4MkG5
RPMI 8226 MlX0R4VtdCCVdYL2bZZidCCDc4PhfS=> MoHGNk81NzZibl2= NX2xdGJPPDkkgJno NXWyXFBpcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NYPrZoE6OjZyMECyPVI>
OPM2 M3fkXGNmdGxiU4Xyeol3[WxiQYPzZZk> NHjxRpMzNzRxNjDuUS=> MWe0PQKBkWh? M3npc4lv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? NWm5VlNuOjZyMECyPVI>
U266 NW\QPIdsS2WubDDTeZJ3cX[jbDDBd5NigQ>? MYCyM|QwPiCwTR?= NV;3UlZtPDkkgJno M2XGSIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? M1Xwb|I3ODByMkmy
H929 M4\wN2NmdGxiU4Xyeol3[WxiQYPzZZk> NVjHSHBNOi92L{[gcm0> NEfF[Fk1QOLCiXi= NVrJOnJWcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NUnhfWlMOjZyMECyPVI>
RPMI 8226  NYT6VlRVSXCxcITvd4l{KEG|c3H5 MYW05qCKdk1? MUSyOE81QCCq M2r5dolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? Mn\aNlYxODB{OUK=
HCC827 M3LkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\lc|lqOTBibl2= M4LkOlQ5KGh? MonESG1UVw>? NUjmfYN{\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= MUGyOVk1PDZzNx?=
NCI-H23 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoThNVAhdk1? MkjaOFghcA>? MnLoSG1UVw>? NHzmbWpmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= M{LnR|I2QTR2NkG3
AML3 MomySpVv[3Srb36gRZN{[Xl? NUHOc3k6OC1zIN88US=> Mln5NlTDqGh? MkTObY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGXzO20zPTZzMkm0NS=>
ML-1 MWPGeY5kfGmxbjDBd5NigQ>? MkLHNE0yKM7:TR?= NUnhVJQ6OjUEoHi= Mn3LbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUDnd4diOjV4MUK5OFE>
RPMI-8226vr10  MVnGeY5kfGmxbjDBd5NigQ>? MWiwMVEh|ryP MmLXNlTDqGh? MoHXbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXLsZoh4OjV4MUK5OFE>
ML-1 NEPyUo5HfW6ldHnvckBCe3OjeR?= M2rwWlEh|ryP MXeyOOKhcA>? NHvETHJqdmO{ZXHz[ZMh[2G|cHHz[U0{KGGldHn2bZR6KDRvZn;s[C=> M{Hj[VI2PjF{OUSx
RPMI-8226vr10  MmDTSpVv[3Srb36gRZN{[Xl? M{TFS|Eh|ryP MlvFNlTDqGh? Ml;KbY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUAzNjVvZn;s[C=> NETuN3kzPTZzMkm0NS=>
SK-N-BE (2) NVziW2c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K1blI16oDLaB?= NGrJ[GtKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= NIHUR5YzPTNyOEmxOi=>
SK-N-BE (2), PAN  MK MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHIU3AzPOLCiXi= NYXVS29lUUN3ME2xNFQvOOLCidMx5qCKPy56IH7N MmH2NlU{ODh7MU[=
SK-N-BE (2), MK  PAN M3HGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj4NIpMOjUkgJno M2C0WGlEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2= NEDSeG8zPTNyOEmxOi=>
SK-N-AS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETRPFUzPOLCiXi= M{DNemlEPTB;M{euNgKBkcLz4pEJNk41KG6P M33GUVI2OzB6OUG2
SK-N-DZ MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\iNlTjiImq NUnKPWlLUUN3ME2xO{4y6oDLwsJihKkxNjRibl2= M2fsV|I2OzB6OUG2
Caki-1 M{TjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;ZXlExNzJ3L{WwJI5O NUHHeGhoPDhiaB?= NVjrdmdEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny M1\SblI2Ojd7MUmx
ACHN NHm5b3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXENVAwOjVxNUCgcm0> M3zKOFQ5KGh? NHfBOJRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NFjIRYgzPTJ5OUG5NS=>
769-P MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17qNlExNzJ3L{WwJI5O NEnkOVA1QCCq M2HHdIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= MmHPNlUzPzlzOUG=
786-O  M4C4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfoSFhmOTBxMkWvOVAhdk1? MXm0PEBp MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? NYPZcXBOOjV{N{mxPVE>
Caki-1 M33JcmFxd3C2b4Ppd{BCe3OjeR?= NF[2S|A2OCCwTR?= MUK0PEBp MlmybY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? MX:yOVI4QTF7MR?=
ACHN MXTBdI9xfG:|aYOgRZN{[Xl? NXm2blJ[PTBibl2= M2C1cVQ5KGh? NHLlW4JqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NYXpUolJOjV{N{mxPVE>
769-P NGTxNXVCeG:ydH;zbZMhSXO|YYm= MWS1NEBvVQ>? NHP1NpU1QCCq NFjNT3lqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= MYGyOVI4QTF7MR?=
786-O  M2\BUGFxd3C2b4Ppd{BCe3OjeR?= MnfCOVAhdk1? M2rSdlQ5KGh? MVfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? MWWyOVI4QTF7MR?=
Caki-1 MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[yOU82OCCwTR?= MVm0PEBp M2DOZ2ROW09? Mo\QbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= M2XUd|I2OTd4M{W0
ACHN NGXiUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\tUnEzPS93MDDuUS=> Mn3qOFghcA>? NYLHOlNVTE2VTx?= M3zQcYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= NX;JO|FxOjVzN{[zOVQ>
769-P NWHOV3ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvCWpgzPS93MDDuUS=> NEXnZYg1QCCq MULEUXNQ M4DuXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= MUSyOVE4PjN3NB?=
Caki-1 NWm3U2p1S2:ub375JGZwem2jdHnvckBCe3OjeR?= MV[1NEBvVQ>? Mn\GO{0yPCCm MnLrSG1UVw>? MnX5d5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> M3LOfFI2OTd4M{W0
ACHN Ml;hR49td267IF\vdo1ifGmxbjDBd5NigQ>? MXW1NEBvVQ>? MXi3MVE1KGR? NYqwNZZZTE2VTx?= MoLTd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> Mm\0NlUyPzZ|NUS=
769-P MmjNR49td267IF\vdo1ifGmxbjDBd5NigQ>? NH7od4U2OCCwTR?= MnnWO{0yPCCm MkDsSG1UVw>? NULV[YRye3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? MnrsNlUyPzZ|NUS=
Caki-1 MYXBdI9xfG:|aYOgRZN{[Xl? NYThUohTPTBibl2= M4rt[|Q5KGh? NUH0N5dbTE2VTx?= MorMbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MXqyOVE4PjN3NB?=
ACHN MkLaRZBweHSxc3nzJGF{e2G7 M4[1dlUxKG6P M2iyNFQ5KGh? MX;EUXNQ NYHwcYhJcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MYeyOVE4PjN3NB?=
769-P NYLzZoF6SXCxcITvd4l{KEG|c3H5 NFW5WXM2OCCwTR?= M1v3dFQ5KGh? M3rmdWROW09? M1vjR4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MWKyOVE4PjN3NB?=
MDA-MB-231 MWTNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> M2nRWFExyqCwTR?= MUGzxsBl NYHHXnhHTE2VTx?= MmThZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi MXiyOFgyODR7Nx?=
BT-549 MXnNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> MYmxNOKhdk1? MV2zxsBl NYLCeXNCTE2VTx?= MmraZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NYHIeVdFOjR6MUC0PVc>
MCF-7  NGPWWG9Od3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl? MX6xNOKhdk1? NXTpdnc5O8LiZB?= MVjEUXNQ Mmj5ZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi MWqyOFgyODR7Nx?=
MCF-7 NUW1eI1lTnWwY4Tpc44hSXO|YYm= MY[1MVUxKG6P MomyNlQhcA>? NG\SZYJFVVOR NEPN[nNz\WS3Y3XkJJRp\SCuZY\lcEBw\iCneIDy[ZN{cW:wIH;mJGVT|rFuIGDSJIFv\CCIb4jBNeKh NXXtXpVQOjR|Nk[0NFc>
CTS Ml\MRZBweHSxc3nzJGF{e2G7 NUfUR3IxOOLCk{SwJI5OyqB? NHLFNYg1QCCq NI[2VGxqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Ml\1NlQzPDR2Mkm=
OCI-AML3  MkS3RZBweHSxc3nzJGF{e2G7 NY\yeXNzOOLCk{SwJI5OyqB? MVW0PEBp MoT1bY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NY\ye4l5OjR{NES0Nlk>
U937 NVTUSm03SXCxcITvd4l{KEG|c3H5 MluyNQKBmzRyIH7NxsA> NWXYU5hyPDhiaB?= Mm\abY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MWSyOFI1PDR{OR?=
PC3 NIDRRm9CeG:ydH;zbZMhSXO|YYm= M{fIOVAuOTByIH7N MmnqNlQwPDhiaB?= MXHpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYmyOFE3OzJ|MB?=
PC3-AR M{fKfGFxd3C2b4Ppd{BCe3OjeR?= MVSwMVExOCCwTR?= M3LIS|I1NzR6IHi= NX;QRmpscW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1:2clI1OTZ|MkOw
PC3 NUXWNGI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fxO|AuOTByIH7N NX3sVnRTOjRxNEigbC=> M4XEOYlv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25? M3zVcVI1OTZ|MkOw
PC3-AR NGfj[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPFNE0yODBibl2= NIDDPIIzPC92ODDo MoezbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckB1cGViR{LNJJBp[XOn MUSyOFE3OzJ|MB?=
PC3 NGjQdFdHfW6ldHnvckBCe3OjeR?= MkTINE0yODBibl2= MVuyOEBp NX;EbXNje3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> MV2yOFE3OzJ|MB?=
PC3-AR NWj2O4ZtTnWwY4Tpc44hSXO|YYm= MmPCNE0yODBibl2= NUK4fYV7OjRiaB?= MnjLd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= MViyOFE3OzJ|MB?=
OS-RC-2 MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUn1[mVEOC1zMECwJI5O MYWyOE81QC95MjDo MmjUSG1UVw>? M3\wWoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVKyOFE1PDd|Nx?=
OS-RC-2 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVeyd|lUPTBibl2= M4q5[lQ5KGh? M4DLeGROW09? Mn\DbY5lfWOnczDHNk9OKGG{cnXzeC=> NH7TSIkzPDF2NEezOy=>
OS-RC-2 NV3jS49OSXCxcITvd4l{KEG|c3H5 NHHDS|U2OCCwTR?= NInt[Gg1QCCq M{XmNGROW09? MULpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NYDUcmJHOjRzNES3N|c>
SK-N-AS M{\qU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvkXlUx6oDVOECgcm0> M{XLeFQ5KGh? NYr6R3JbUUN3ME2yO{41KG6P NVniPFZyOjRyOUi3PVk>
SK-N-DZ NVnVZ3VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K4bVDjiJN6MDDuUS=> NH7ZfY81QCCq NVrxW3g3UUN3ME2yNU46KG6P NEj4WYczPDB7OEe5PS=>
SK-N-SH NV\Id2lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DTcFDjiJN6MDDuUS=> MlXROFghcA>? NHrw[nhKSzVyPUeyMlMhdk1? NHP2W5czPDB7OEe5PS=>
SK-N-BE MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7pcWV5OOLCk{iwJI5O M3TZN|Q5KGh? NXvvblRoUUN3ME23OU41KG6P NF;nOIwzPDB7OEe5PS=>
SK-N-AS M4W4PWFxd3C2b4Ppd{BCe3OjeR?= NFHIPGsx6oDVOECgcm0> NHvkcnc1QCCq NYXUbnF3eG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v MmXlNlQxQTh5OUm=
SK-N-DZ MknCRZBweHSxc3nzJGF{e2G7 MXyw5qCUQDBibl2= NGDxfXY1QCCq MojpdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MXSyOFA6QDd7OR?=
SK-N-SH NXPBUmlCSXCxcITvd4l{KEG|c3H5 NHvGV2Ex6oDVNECgcm0> NIDlW201QCCq M33xdpBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> MVOyOFA6QDd7OR?=
SK-N-BE M4j6UGFxd3C2b4Ppd{BCe3OjeR?= MlLvNQKBmzRyIH7N NHvDPWw1QCCq Mn7tdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u M1\zUlI1ODl6N{m5
SK-N-AS NFflSnhHfW6ldHnvckBCe3OjeR?= NGXjPIkx6oDVOECgcm0> MUG0PEBp MYXpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ M{K3eVI1ODl6N{m5
SK-N-DZ M3HOUGZ2dmO2aX;uJGF{e2G7 M4j6XVDjiJN6MDDuUS=> MWS0PEBp NHHueIRqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR MlPTNlQxQTh5OUm=
SK-N-SH MYfGeY5kfGmxbjDBd5NigQ>? M{HQWFDjiJN2MDDuUS=> M1f2fFQ5KGh? NXLlOph2cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? NEjZVIszPDB7OEe5PS=>
SK-N-BE NGXI[3VHfW6ldHnvckBCe3OjeR?= MmjmNQKBmzRyIH7N NGDBW|M1QCCq NEnhPVhqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR MlnwNlQxQTh5OUm=
HCC-LM3 NIf4O3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz0cFIyNTFyMECgcm0> M4H3fVI1NzR6L{eyJIg> M{T4OWROW09? NU\QdWZxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXm0Sm06OjRyOUO5OVY>
HepG2 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnPXm0yNTFyMECgcm0> NX35cG06OjRxNEivO|IhcA>? NV\XVmJjTE2VTx?= MWfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYO5bGRKOjRyOUO5OVY>
SMMC-7721 NIj0OY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7XNU0yODByIH7N NVn6VplROjRxNEivO|IhcA>? NFTyenZFVVOR Mn:0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWnvTXRpOjRyOUO5OVY>
HCC-LM3 NUjJOFNYSXCxcITvd4l{KEG|c3H5 MWe1NEBvVQ>? NGqzNXo1QCCq MlzTSG1UVw>? MnLibY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> NUT0cYY2OjRyOUO5OVY>
HepG2 MV\BdI9xfG:|aYOgRZN{[Xl? NFzFVnE2OCCwTR?= NUjqRlBHPDhiaB?= NVvhWGRmTE2VTx?= NF3NOXRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[ZMhOyxiODDhcoQhQQ>? M{L1XVI1ODl|OUW2
SMMC-7721 NIf0NmVCeG:ydH;zbZMhSXO|YYm= M2j3fFUxKG6P NWTo[HhFPDhiaB?= MWfEUXNQ NYDXfZBRcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? NVvEOY54OjRyOUO5OVY>
HCC-LM3 Mm\NSpVv[3Srb36gRZN{[Xl? MkfSOVAwOTByIH7N Mm\yNlQhcA>? NF3rW5BFVVOR M4n3doRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= MlTsNlQxQTN7NU[=
HepG2 NV[3Zot{TnWwY4Tpc44hSXO|YYm= NXfQ[5ZIPTBxMUCwJI5O NEnNO4IzPCCq NIX2ZZpFVVOR M2nVdoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= MXyyOFA6Ozl3Nh?=
SMMC-7721 MYTGeY5kfGmxbjDBd5NigQ>? MnHIOVAwOTByIH7N MXqyOEBp MYHEUXNQ NUfCOXZx\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> MXOyOFA6Ozl3Nh?=
HCC-LM3 MlfqSpVv[3Srb36gRZN{[Xl? MXe1NE8yODBibl2= MkLqNlQhcA>? NYDP[IZRTE2VTx?= Mn3K[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? NWO4dndvOjRyOUO5OVY>
HepG2 M2rteGZ2dmO2aX;uJGF{e2G7 Mn3TOVAwOTByIH7N M3mxeVI1KGh? NF\MeFBFVVOR NHW5TYZld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w NY\C[GE{OjRyOUO5OVY>
SMMC-7721 MV7GeY5kfGmxbjDBd5NigQ>? NX3t[YZqPTBxMUCwJI5O NUHM[GY{OjRiaB?= M13GVGROW09? MVPkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v MlHINlQxQTN7NU[=
FaDu MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTjNVAx6oDHbl2= NITyPWE5NzFyL{GyJIg> MlPF[Il{eGyjeXXkJIEhe2mpbnnmbYNidnRiYX7kJJBzd2yxbnfl[EBIOi:PIHHydoV{fCCjdDC4JIFv\CBzMvMAiYgheG:|dDDy[Yxm[XOn MY[yOFAzPjR6Mh?=
FaDu NWjRWZdWTnWwY4Tpc44hSXO|YYm= Mnm4NVAx6oDHbl2= MlHSNk81NzhxMUKgbC=> NGDOeHBqdmS3Y3XkJJAzOVejZkGvR4lxOcLiZYjwdoV{e2mxbh?= MWSyOFAzPjR6Mh?=
PC-3  NWTtdXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f2bFAuOTBizszN Ml36NlQwPDhxN{KgbC=> MkW2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NETCZpEzOzl7MUKxOi=>
LNCaP M1\tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm4SIIxNTVizszN NVLWUXZVOjRxNEivO|IhcA>? MoHhbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGfYfm0zOzl7MUKxOi=>
RWPE-1  MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGwMVIxKM7:TR?= NWLsfVVFOjRxNEivO|IhcA>? MlGybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Ml7HNlM6QTF{MU[=
Capan-1 MmO5SpVv[3Srb36gRZN{[Xl? NYLGT497OjVxNUCvNVAxKG6P MlLUPE8zPC92ODDo M13FeGROW09? NEL1ZYpld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n NIWwXZUzOzl{Mki4Oi=>
L3.6pl NVzU[ldjTnWwY4Tpc44hSXO|YYm= MYOyOU82OC9zMECgcm0> NVHi[nBVQC9{ND:0PEBp M2LLc2ROW09? MWfkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p MY[yN|kzOjh6Nh?=
CFPAC-1  M{W1fWZ2dmO2aX;uJGF{e2G7 MUOyOU82OC9zMECgcm0> NEPmVZk5NzJ2L{S4JIg> MUXEUXNQ NF7VZ2pld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n NGfne5EzOzl{Mki4Oi=>
Capan-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWSyb5BuOjVxNUCvNVAxKG6P NVn0N2xSPDhiaB?= M3zjOWROW09? MWXy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NIDKbXAzOzl{Mki4Oi=>
L3.6pl MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKyOU82OC9zMECgcm0> MnLmOFghcA>? MoPESG1UVw>? M{L6cJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NF;WUlUzOzl{Mki4Oi=>
CFPAC-1  NVXaTmJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPMPHQzPS93MD:xNFAhdk1? MUe0PEBp NFfOfmFFVVOR M4HUcJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NGPKSXUzOzl{Mki4Oi=>
Capan-1 NYHkUGlpSXCxcITvd4l{KEG|c3H5 NIPXeIwzPS93MD:xNFAhdk1? NWXNTJVKPDhiaB?= MVnEUXNQ NHTnbJRqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NETsXYszOzl{Mki4Oi=>
L3.6pl MlvmRZBweHSxc3nzJGF{e2G7 MorZNlUwPTBxMUCwJI5O NXTafYIxPDhiaB?= MXzEUXNQ M3XMWYlv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnHzNlM6OjJ6OE[=
CFPAC-1  NXHYOYF7SXCxcITvd4l{KEG|c3H5 NF61RXUzPS93MD:xNFAhdk1? M3\IUlQ5KGh? MkTqSG1UVw>? MXPpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MknnNlM6OjJ6OE[=
HN22 NWT0ZnRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCwMVIxKG6P MlO1NlQwPDhiaB?= MoPWSG1UVw>? Mki3bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NEHRSHUzOzh5N{KzOS=>
HSC4  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrRd5JiOC1{MDDuUS=> NXznXIVQOjRxNEigbC=> MlrYSG1UVw>? NFnjZ2lqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz NUfyeZFWOjN6N{eyN|U>
HN22 MnPERZBweHSxc3nzJGF{e2G7 M{TuSlAuOjBibl2= NGrlcXM1QCCq M{S0UmROW09? MXXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NXfRWGo4OjN6N{eyN|U>
HSC4  MVzBdI9xfG:|aYOgRZN{[Xl? NFK3bXExNTJyIH7N MX[0PEBp NVzydIc6TE2VTx?= MYPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVyyN|g4PzJ|NR?=
HN22 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkGzNE0zOCCwTR?= M33WdVQ5KGh? NIGxTVBFVVOR MnzKbY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dNMg Ml2wNlM5Pzd{M{W=
HSC4  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoCwNE0zOCCwTR?= MkTNOFghcA>? MWPEUXNQ M3G4OIlv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> NWnPcYtYOjN6N{eyN|U>
HN22 NWH5V4xGTnWwY4Tpc44hSXO|YYm= NGjYSVExNTJyIH7N M1TpZlQ5KGh? NXyyV3dMTE2VTx?= M4H4N5N2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=> NG\NTGozOzh5N{KzOS=>
HSC4  MXTGeY5kfGmxbjDBd5NigQ>? MV[wMVIxKG6P MmSzOFghcA>? M{fvbWROW09? MoK0d5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg MWmyN|g4PzJ|NR?=
Cal62 NUXrOpVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTN|INMxJFQhdk1? MXWyN|gzPDB4NB?=
Hth7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz5PXlDUUN3ME2xOUDDuSB{IH7N NVHlU2xtOjN6MkSwOlQ>
Hth83 NHXoOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoryTWM2OD1|NDFCtUA2KG6P M2fTelI{QDJ2ME[0
C643 M3e2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTdzINMxJFExKG6P MkDSNlM5OjRyNkS=
SW1736 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjyTWM2OD1|NTFCtUA5KG6P M4fkXFI{QDJ2ME[0
T241 NXi2T5U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPtSFlyUUN3ME22OUDDuSB5IH7N MkPqNlM5OjRyNkS=
T351 NFS1OYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\RU2lEPTB;NUCgxtEhOTBibl2= MXGyN|gzPDB4NB?=
BHP2-7 Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH3ZZl{UUN3ME2zO{DDuSB4IH7N NUPFZlczOjN6MkSwOlQ>
T238 NHfMS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DJS2lEPTB;MTy1NFAhyrFiMkCwJI5O Moi1NlM5OjRyNkS=
HCT8 M3TQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e1bFczKGh? NGLOVG5FVVOR NVzlNXJOUUN3ME2xNk466oDLwsJihKkyNjlibl2= NYLRdYVnOjN{OUmzPFg>
H630 NE\BN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH4N3U4OiCq MoTXSG1UVw>? MlvuTWM2OD1zMj605qCKyrIkgJmzMlEhdk1? NW[4VG1[OjN{OUmzPFg>
cH630 5-FU-res NHThd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVq3NkBp NFzMN3dFVVOR MnLoTWM2OD1zNT615qCKyrIkgJmxMlIhdk1? NGPwNVUzOzJ7OUO4PC=>
HCT116 NXjXc4pjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLxfI93PzJiaB?= M{Kwb2ROW09? M1nWNGlEPTB;MUCuO-KBkcLz4pEJNk4zKG6P MYeyN|I6QTN6OB?=
HCT116 p53−/− MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;OXpJrPzJiaB?= NHLzXIZFVVOR MX;JR|UxRThwNvMAjeKy6oDLMT63JI5O NYLzT2lnOjN{OUmzPFg>
dHCT116 p21−/− NV;lNnltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[3NkBp NX;N[XBITE2VTx?= MnfaTWM2OD13LkpihKnDueLCiUGuN{BvVQ>? MWSyN|I6QTN6OB?=
HT29 NH3sN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLsNWM4OiCq MUDEUXNQ MnnwTWM2OD1zNj6z5qCKyrIkgJmyMlMhdk1? M3zwS|I{Ojl7M{i4
LoVo MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rmOFczKGh? NFu4dZhFVVOR M3nBeGlEPTB;NT6x5qCKyrIkgJmwMlYhdk1? NIjpd4czOzJ7OUO4PC=>
RKO MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[3NkBp NUHmUHBnTE2VTx?= MYrJR|UxRTdwOfMAjeKy6oDLMj6yJI5O NY\yO2RPOjN{OUmzPFg>
SW480 NYPpbZRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjqS5VMPzJiaB?= NYPu[2VJTE2VTx?= M33tbWlEPTB;MUeuOgKBkcLz4pEJNE45KG6P NFfufnIzOzJ7OUO4PC=>
eSW620 NHG4[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3lO|IhcA>? MUDEUXNQ MXrJR|UxRTlwMfMAjeKy6oDLMj6xJI5O NYDCR3NjOjN{OUmzPFg>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
体内研究 LBH589作用于患肺癌和间皮瘤动物模型,明显降低肿瘤生长,与对照组相比平均降低62%。LBH589作用于免疫活性鼠和严重联合免疫缺陷鼠效果差不多,说明LBH589抑制肿瘤生长与免疫学无关。LBH589按20 mg/kg剂量腹腔注射,每周持续5天,导致在实验最后肿瘤生长平均下降70%。与相应的对照组肿瘤相比,LBH589作用于H526衍生的肿瘤下降53%,作用于BK-T衍生的肿瘤下降81%, 作用于RG-1衍生的肿瘤下降76%,作用于H69衍生的肿瘤下降 70%。在相同条件和剂量的情况下,LBH589 作用于NSCLC和Meso衍生的移植瘤,导致SCLC衍生的肿瘤中有两种衰退,伴随着BK-T衍生的平均肿瘤尺寸从实验开始时的296 mm3降低到实验结束时的116 mm3,RG-1衍生的平均肿瘤尺寸从实验开始时的185mm3降低到实验结束时的86 mm3[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: MOLT-4细胞和Reh(前体B细胞)
  • Concentrations: 50 nM
  • Incubation Time: 48小时
  • Method: 没有处理的细胞和LBH589处理的细胞[人类急性成淋巴细胞性白血病MOLT-4(T 细胞)和Reh(前体-B细胞)]用膜联蛋白V和碘化丙啶染色,然后加入膜联蛋白V-FITC细胞凋亡检测试剂盒I。通过流式细胞仪测定细胞凋亡和不能存活细胞的百分比。用CyAn ADP Violet细胞计数器收集至少5×104个细胞。根据所有的膜联蛋白V-阳性和膜联蛋白V/PI-阳性细胞细胞计算凋亡百分比,根据所有的膜联蛋白V-阳性和PI-阳性及膜联蛋白V/PI-阳性细胞计算细胞活力丢失百分比。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: 携带10×106个M30细胞或5×106个A549细胞的SCID鼠
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 349.43
化学式

C21H23N3O2

CAS号 404950-80-7
储存条件 粉状
溶于溶剂
别名 NVP-LBH589

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04341311 Recruiting Drug: Marizomib|Drug: Panobinostat Diffuse Intrinsic Pontine Glioma|Pediatric Brainstem Glioma|Pediatric Brainstem Gliosarcoma Recurrent|Pediatric Cancer|Pediatric Brain Tumor|Diffuse Glioma Dana-Farber Cancer Institute|Celgene|Secura Bio August 2020 Phase 1
NCT03632317 Withdrawn Drug: Panobinostat|Drug: Everolimus Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Drug: PDR001|Drug: Panobinostat Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT04326764 Recruiting Drug: Panobinostat Acute Myeloid Leukaemia (AML)|Myelodysplastic Syndromes (MDS) Goethe University|Jan J. Cornelissen (HOVON-SAKK)|Sebastian Giebel (PALG) July 24 2018 Phase 3
NCT03515915 Unknown status -- Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo mice study?

  • 回答:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Panobinostat (LBH589) | Panobinostat (LBH589)供应商 | 采购Panobinostat (LBH589) | Panobinostat (LBH589)价格 | Panobinostat (LBH589)生产 | 订购Panobinostat (LBH589) | Panobinostat (LBH589)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID